reviewed april 2026|next review october 2026|88 physicians psi has verified|26227 published studies
Neuromedin U
Neuromedin U (NMU) is a 25-amino-acid neuropeptide that potently suppresses appetite and increases energy expenditure through NMUR1 (peripheral) and NMUR2 (central nervous system) receptors, operating through a signaling pathway entirely independent of GLP-1, with NMU knockout mice developing obesity as confirmation of its physiological role in energy balance.
Evidence landscape: 26227 published studies
Published studies indexed under this compound. The NMU literature is growing as obesity drug target research expands beyond GLP-1.
- 38 Human
- 124 Animal
- 38 Reviews
- 26027 Other research
Not FDA-approved. No NMU-based drug is in clinical development. Long-acting NMUR2 agonists are in early development with animal studies by several pharmaceutical groups.
Not commercially available as a therapeutic. Naturally occurring neuropeptide widely expressed in the gut and brain. Available as a research compound from specialty suppliers.
One of several naturally occurring appetite-suppressing neuropeptides being explored as obesity drug targets. The independent pathway from GLP-1 signaling makes NMU theoretically interesting as a combination partner, but drug development is years behind the GLP-1 class.
PSI Assessment
Among the next wave of potential obesity targets beyond GLP-1, neuromedin U stands out because it operates through a completely independent receptor system. When NMU activates NMUR2 in the brain's hypothalamus, food intake drops and energy expenditure rises. Mice engineered to lack NMU become obese, confirming this is not just a pharmacological effect but a genuine physiological role in energy balance. The independence from GLP-1 signaling raises the theoretical possibility of combination approaches, but no NMU-based drug has entered clinical trials.
Potent appetite suppression through a pathway entirely independent of GLP-1. NMU knockout mice develop obesity. No drug in clinical development.
The mechanism involves two Gq-coupled receptors with distinct tissue distributions. NMUR2 in the hypothalamic paraventricular nucleus mediates the central appetite-suppressing and energy-expenditure effects. NMUR1 in peripheral tissues modulates immune cell function, gut motility, and inflammatory responses. The dual receptor system means NMU biology spans both metabolic and immune regulation.
What the evidence supports
NMU potently suppresses appetite through central NMUR2 activation in multiple animal species. NMU knockout mice develop obesity, confirming a physiological role in energy balance. The dual receptor system (NMUR1 peripheral, NMUR2 central) is well characterized. The appetite-suppressing pathway is independent of GLP-1, GIP, and glucagon receptor signaling.
What is not yet established
Whether NMU-based therapeutics can achieve the pharmacokinetic profile needed for human clinical use. Human efficacy and safety data for any NMU-based compound. Whether NMU agonists can compete with or complement established GLP-1 therapies for weight management.
Research Evidence
The findings below cover what animal models (animal research) have established about NMU's metabolic role and the obstacles to therapeutic development.
Evidence by condition
Evidence dimensions across NMU research areas. Appetite and obesity have the deepest animal study data. Energy expenditure and stress response are characterized in animal models. Circadian effects are less established.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Appetite/Obesity | ||||
| Energy Expenditure | ||||
| Stress Response | ||||
| Circadian Rhythm |
Central administration of NMU potently suppresses food intake in rats and mice through NMUR2 activation in the hypothalamic paraventricular nucleus. The anorexigenic effect is independent of GLP-1 receptor signaling.
The appetite-suppressing potency is comparable to other neuropeptide systems being targeted for obesity. The key question is whether long-acting analogs can deliver sustained effect without the limitations of the native peptide's short half-life.
NMU knockout mice develop late-onset obesity and glucose intolerance, confirming that NMU plays a physiological (not just pharmacological) role in maintaining energy balance.
Genetic validation is one of the strongest forms of evidence for a drug target. The late-onset phenotype suggests NMU is more important for maintaining metabolic health over time than for acute appetite regulation.
NMU also activates mast cells and contributes to allergic inflammation through peripheral NMUR1. NMU-deficient mice show reduced allergic responses.
The immune connection complicates therapeutic development. An NMUR2-selective agonist that avoids NMUR1-mediated immune activation would be the ideal drug candidate. Achieving this receptor selectivity is an active area of medicinal chemistry research.
38 Human|124 Animal|38 Reviews
View all 26227 indexed studiesHow Neuromedin U Works
NMU tells the brain to stop eating and tells the body to burn more energy. It works through its own dedicated receptors, a pathway completely independent of GLP-1. Think of it as a separate volume dial for appetite that the body can turn independently of the GLP-1 system.
NMU tells the brain to stop eating and tells the body to burn more energy. It works through its own dedicated receptors (NMUR1 and NMUR2), a pathway completely independent of GLP-1. This independence makes it interesting as a potential combination target.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
NMU-25 (the human form) signals through NMUR1 (Gq-coupled, expressed in peripheral tissues including gut, lung, and immune cells) and NMUR2 (Gq-coupled, expressed predominantly in the CNS, particularly the hypothalamic paraventricular nucleus). Central NMUR2 activation suppresses food intake via phospholipase C signaling and increases energy expenditure through sympathetic nervous system activation. NMU also modulates the HPA (hypothalamic-pituitary-adrenal) axis stress response via CRH (corticotropin-releasing hormone) neurons. Native peptide half-life is short, requiring analog development for therapeutic use.
What is Neuromedin U being studied for?
Researchers are studying Neuromedin U across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Neuromedin U overall. This means a compound can have human studies for one condition but only animal data for another.
Appetite/Obesity
·Animal StudiesNMU potently suppresses appetite through central NMUR2 activation in multiple animal species. NMU knockout mice develop obesity, providing genetic validation of this pathway as a genuine physiological regulator of energy balance.
Limitations: No human clinical data. No NMU-based drug in clinical development. The competitive landscape against approved GLP-1 therapies is challenging. Native peptide half-life requires analog development.
Energy Expenditure
·Animal StudiesCentral NMU administration increases energy expenditure through sympathetic nervous system activation in animal models (animal research).
Limitations: Energy expenditure effects characterized only in animal models. Whether NMU-mediated thermogenesis translates to meaningful metabolic benefit in humans is untested.
Stress Response
·Animal StudiesNMU modulates the HPA axis stress response through CRH neuron activation in animal models (animal research).
Limitations: The stress-response activation is a potential safety concern rather than a therapeutic benefit. An ideal NMUR2 agonist would suppress appetite without excessive HPA axis activation.
Circadian Rhythm
·PreclinicalNMU expression follows circadian patterns and may modulate circadian feeding behavior in animal models.
Limitations: Circadian role is the least characterized aspect of NMU biology. Evidence is limited to expression pattern data.
Safety and Regulatory Status
FDA Status: Not FDA-approved. No NMU-based therapeutic exists or is in clinical development.
Availability: Not commercially available as a therapeutic. Available as a research compound from specialty suppliers.
Class context: Naturally occurring neuropeptide. NMU also activates the HPA stress axis, which could cause cortisol elevation and anxiety-like effects if not managed through receptor-selective drug design. This is a key safety consideration for future therapeutic development.
NMU is naturally occurring with no safety concerns from normal physiology. The key safety consideration for future therapeutics is that NMU activates the HPA stress axis in addition to suppressing appetite. An ideal drug would achieve NMUR2 selectivity for appetite suppression while avoiding stress-response activation and NMUR1-mediated immune effects.
Questions and Comparisons
Questions the evidence raises for a Neuromedin U discussion.
Comparison and Related Research
NMU is compared with other appetite-suppressing pathways being targeted for obesity treatment.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Identified NMUR1 and NMUR2 as the receptors for neuromedin U and demonstrated that central NMU administration potently suppressed food intake in rats. This study established NMU as an anorexigenic neuropeptide and positioned it as a potential anti-obesity target through a pathway independent of GLP-1.Howard AD et al., 2000 in Nature. View on PubMed
- 2.Demonstrated that mice lacking neuromedin U developed obesity and glucose intolerance as adults, confirming that NMU plays an essential role in maintaining normal energy balance. This genetic evidence strengthened the case for NMU as a physiologically relevant appetite-regulating peptide.Peier AM et al., 2009 in Endocrinology. View on PubMed
- 3.Revealed that neuromedin U directly activates mast cells and contributes to allergic airway inflammation. NMU-deficient mice showed reduced allergic responses, demonstrating a link between this metabolic neuropeptide and immune regulation that was previously unrecognized.Moriyama M et al., 2006 in J Immunol. View on PubMed
- 4.Reviewed the drug development landscape for NMUR2-selective agonists targeting obesity. The paper described medicinal chemistry efforts to create long-acting NMU analogs that overcome the native peptide's short half-life, positioning NMUR2 as an independent anti-obesity target distinct from GLP-1 receptor pathways.Raddatz R et al., 2017 in Front Pharmacol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.